Investors sold shares of Allergan PLC (NYSE:AGN) on strength during trading hours on Wednesday. $490.72 million flowed into the stock on the tick-up and $573.65 million flowed out of the stock on the tick-down, for a money net flow of $82.93 million out of the stock. Of all equities tracked, Allergan PLC had the 0th highest net out-flow for the day. Allergan PLC traded up $11.29 for the day and closed at $260.24

Several research analysts recently issued reports on the stock. Leerink Swann increased their price target on shares of Allergan PLC from $272.00 to $294.00 and gave the stock an “outperform” rating in a research report on Wednesday. Zacks Investment Research lowered shares of Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday. Vetr raised shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price objective for the company in a report on Monday. Credit Suisse Group AG started coverage on shares of Allergan PLC in a report on Monday. They set an “outperform” rating and a $327.00 price objective for the company. Finally, Mizuho reaffirmed a “hold” rating and set a $232.00 price objective on shares of Allergan PLC in a report on Monday, July 11th. Seven investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $308.74.

The company has a 50 day moving average of $239.38 and a 200 day moving average of $254.17. The company has a market capitalization of $102.94 billion and a price-to-earnings ratio of 23.29.

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 10th. The company reported $3.04 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.01. The business earned $3.80 billion during the quarter, compared to the consensus estimate of $3.97 billion. The firm’s revenue for the quarter was up 48.1% compared to the same quarter last year. On average, analysts forecast that Allergan PLC will post $14.17 earnings per share for the current fiscal year.

In other news, Director Nesli Basgoz sold 459 shares of the stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total value of $103,320.90. Following the completion of the sale, the director now owns 5,242 shares in the company, valued at $1,179,974.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Maria Teresa Hilado bought 661 shares of the stock in a transaction dated Thursday, June 2nd. The stock was purchased at an average price of $241.57 per share, with a total value of $159,677.77. Following the acquisition, the chief financial officer now owns 11,957 shares of the company’s stock, valued at $2,888,452.49. The disclosure for this purchase can be found here.

Several hedge funds have recently made changes to their positions in AGN. Wetherby Asset Management Inc. increased its stake in shares of Allergan PLC by 0.7% in the fourth quarter. Wetherby Asset Management Inc. now owns 26,866 shares of the company’s stock valued at $8,395,000 after buying an additional 179 shares in the last quarter. Quantitative Investment Management LLC purchased a new stake in shares of Allergan PLC during the fourth quarter valued at approximately $8,156,000. Blume Capital Management Inc. increased its stake in shares of Allergan PLC by 12,641.7% in the fourth quarter. Blume Capital Management Inc. now owns 15,290 shares of the company’s stock valued at $4,778,000 after buying an additional 15,170 shares in the last quarter. Fishman Jay A Ltd. MI increased its stake in shares of Allergan PLC by 36.3% in the fourth quarter. Fishman Jay A Ltd. MI now owns 58,808 shares of the company’s stock valued at $18,378,000 after buying an additional 15,653 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in shares of Allergan PLC by 149.3% in the fourth quarter. Moors & Cabot Inc. now owns 3,498 shares of the company’s stock valued at $1,095,000 after buying an additional 2,095 shares in the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.